Cerus stock has November 5, 2026 earnings date and USD 63.25 million estimate

Published on 10/17/2026 at 19:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 63.30 million in the second quarter. Cerus stock closed at USD 2.18 on October 16, 2026, down 3.54 percent versus the Nasdaq close.

Results timing and stock metrics

Cerus is estimated to report third-quarter results on November 5, 2026, with USD 63.25 million in expected revenue.
Second-quarter revenue reached USD 63.30 million against a USD 62.90 million consensus estimate on July 30, 2026.
Cerus stock closed at USD 2.18 on October 16, 2026, down 3.54 percent versus the Nasdaq prior close.
Cerus had a USD 439.3 million market capitalization and a price-to-earnings ratio of minus 60.22 on October 16, 2026.

CERS, US1570851014, Illustration mit AI erstellt.

Cerus Corporation (ISIN US1570851014) is estimated to report its third-quarter results on November 5, 2026, with consensus revenue of USD 63.25 million, according to MarketBeat on October 14, 2026. The date is the next calendar marker for Cerus stock.

MarketBeat reported that second-quarter revenue reached USD 63.30 million on July 30, 2026, compared with a USD 62.90 million consensus estimate. That represents a 0.64 percent increase over expectations, while earnings per share came to a loss of USD 0.01, matching consensus.

Range leaves stock below its high

Cerus closed at USD 2.18 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 3.54 percent from the prior close of USD 2.26. The stock stood 37.18 percent below its 52-week high of USD 3.47 and 57.97 percent above its 52-week low of USD 1.38.

Trading volume reached 2,406,222 shares on October 16, 2026, versus an average volume of 2,171,456 shares. The comparison places the latest session above Cerus' recent trading average, while the closing price remained below both the 50-day average of USD 2.56 and the 200-day average of USD 2.54 reported by MarketBeat on October 14, 2026.

Valuation remains tied to losses

Cerus had a market capitalization of USD 439.3 million and a price-to-earnings ratio of minus 60.22 as of October 16, 2026. The negative ratio reflects the company's loss-making earnings base rather than a conventional profit multiple.

The next report will therefore put revenue execution and the path toward profitability back at the center of the market discussion. Cerus develops the INTERCEPT Blood System for pathogen reduction in donated blood components, including platelet and plasma products.

Comparison with peers

Cerus Corporation (Nasdaq, USD): minus 3.54 percent, price-to-earnings ratio minus 60.22, market capitalization USD 439.3 million, as of October 16, 2026.

Becton, Dickinson and Company (NYSE, USD): minus 1.04 percent, price-to-earnings ratio 57.76, market capitalization USD 52.2 billion, as of October 16, 2026.

Thermo Fisher Scientific (NYSE, USD): minus 0.93 percent, price-to-earnings ratio 37.12, market capitalization USD 255.1 billion, as of October 16, 2026.

November sets the next marker

The November 5 reporting date gives investors a defined point for testing the USD 63.25 million revenue estimate against Cerus' second-quarter performance. The Nasdaq closing price of USD 2.18 on October 16, 2026 at 4:00 p.m. ET leaves the stock below its yearly high and above its yearly low.